59447-12-0 Usage
General Description
3-OXO-3-(4-PHENOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER, also known as fenbufen, is a chemical compound that belongs to the nonsteroidal anti-inflammatory drug (NSAID) class. It is commonly used for its anti-inflammatory, analgesic, and antipyretic properties in the treatment of various conditions such as rheumatoid arthritis, osteoarthritis, and musculoskeletal pain. Fenbufen acts by inhibiting the production of prostaglandins, which are chemical compounds that mediate inflammation, pain, and fever in the body. As an ethyl ester, it is the ethyl ester of fenbufen and is often used to improve the solubility and bioavailability of the drug in pharmaceutical formulations. Overall, fenbufen is an important chemical used in the treatment of pain and inflammation.
Check Digit Verification of cas no
The CAS Registry Mumber 59447-12-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,4,4 and 7 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 59447-12:
(7*5)+(6*9)+(5*4)+(4*4)+(3*7)+(2*1)+(1*2)=150
150 % 10 = 0
So 59447-12-0 is a valid CAS Registry Number.
InChI:InChI=1/C17H16O4/c1-2-20-17(19)12-16(18)13-8-10-15(11-9-13)21-14-6-4-3-5-7-14/h3-11H,2,12H2,1H3
59447-12-0Relevant articles and documents
PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES
-
Paragraph 0127; 0128, (2018/12/13)
The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt
SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
-
Page/Page column 74, (2015/04/15)
Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
-
Paragraph 0124; 0125, (2014/09/29)
The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
